Below is a summary of our recent news. Click any post title or the read more link below any story to see more!
The American Thyroid Association will convene this week in Victoria, BC for its 87th Annual Meeting! If you are in the area, please check out these events for both patients and physicians!
PATIENTS: The GDATF is excited to be participating in the ATA's Alliance for Patient Education Public Health Forum this Saturday, October 21 from 2-4 p.m. at the Fairmont Empress. This will be an excellent opportunity to ask questions of thyroid experts and patient advocates. Please click this link for more info from the American Thyroid Association!
PHYSICIANS: On Friday, October 20th at 6:00 a.m., Quidel will host an early riser satellite symposium, "TSH Receptor Antibodies: Methodology and Clinical Relevance." Please click here to view the event flyer or to RSVP.
Registration is now open for our FREE patient education events in Baltimore and Boston!
Baltimore: Sunday, Oct. 8th (during the ThyCa annual meeting for thyroid cancer survivors).
Click here for Baltimore Registration.
A diagnosis of Graves’ disease or thyroid eye disease is life-changing: insomnia, mood swings, fatigue, eye bulging, double vision and SO much more. Take charge by learning about treatment options from experts in the field and by connecting with fellow patients! Click here to register online or call 877-643-3123 to reserve your space!
Date: Saturday, October 14, 2017
Time: 7:30 AM-12:00 PM
Location: Mass. Eye and Ear, 243 Charles Street, Meltzer Auditorium (3rd floor) Boston, MA 02214
The Graves' Disease & Thyroid Foundation's offices will be closed on July 1st - 4th. We would like to wish everyone a safe and happy 4th of July holiday!
If you've been diagnosed with thyroid eye disease, you know that the current options leave much to be desired: wait, wait, wait, wait some more -- and eventually get approved for one or more surgeries to address bulging, swelling, and double vision. (With steroid therapy sometimes used as a temporary stopgap). However, the successful trial of a brand new drug could prove to be a game-changer for patients living with this disfiguring and frustrating condition. The New England Journal of Medicine recently published "Teprotumumab for Thyroid-Associated Ophthalmopathy". The authors included GDATF Chief Medical and Scientific Officer Dr. Terry Smith as well as GDATF Physician Advisory Board Members Dr. Raymond Douglas and Dr. George Kahaly. To learn more, please click here for an article from Science Daily or click here to visit Dr. Douglas' Facebook Page.